Literature DB >> 3999028

Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling.

M M Hammarlund, B Odlind, L K Paalzow.   

Abstract

Furosemide, 40 mg, was given to eight healthy volunteers as an i.v. dose and as oral doses (tablet and solution) with and without food intake. The urine and plasma were sampled frequently and analyzed on their content of furosemide (high-performance liquid chromatography). The urine flow and chloride excretion rate were used as measures of the effect. In spite of a 3-fold difference (28 vs. 9 mg/8 hr, P less than .001) in the cumulative urinary excretion of furosemide between i.v. and postprandial oral administration, no significant difference in the diuretic effect was found (2-2.2 liters/8 hr). The drug excretion-response curves showed parallel shifts depending on mode of administration of furosemide. Clockwise hysteresis, indicating acute tolerance development to the diuretic effect, was seen after the oral doses after food intake. This within-dose development of tolerance was modeled with an extended Hill equation. The tolerance development seems to have a near relationship to acute volume depletion (inadequate substitution of urine losses), probably activating some intrarenal mechanism for extracellular fluid volume preservation. Thus, the time course of furosemide excretion, as well as the degree of renal compensation, determine the renal sensitivity to furosemide. This has important implications for the proper design and interpretation of studies of the excretion-response relationship of diuretics.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3999028

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  41 in total

1.  The influence of frusemide formulation on diuretic effect and efficiency.

Authors:  M Wakelkamp; A Blechert; M Eriksson; K Gjellan; C Graffner
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

3.  The validity of the sigmoid Emax model and efficiency concept in diuretic studies.

Authors:  G Alván; M Hammarlund-Udenaes; B Odlind
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  Response to furosemide during dehydration with and without naproxen pretreatment of kidney donors and renal transplant recipients.

Authors:  P A Sjöström; B G Odlind; M Hammarlund-Udenaes
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

6.  Absence of tolerance and toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery.

Authors:  Maria M J van der Vorst; Joana E Kist-van Holthe; Jan den Hartigh; Albert J van der Heijden; Adam F Cohen; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

7.  Optimization of the therapeutic index by adjustment of the rate of drug administration or use of drug combinations: exploratory studies of diuretics.

Authors:  J Zhi; G Levy
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

8.  Use of Emax model in diuretic studies.

Authors:  F H Noormohamed
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

9.  Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors:  K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

Review 10.  Methodological issues in pharmacokinetic-pharmacodynamic modelling.

Authors:  E Bellissant; V Sébille; G Paintaud
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.